HK1191330A1 - 作為 的正變構調節劑的乙炔基衍生物 - Google Patents

作為 的正變構調節劑的乙炔基衍生物

Info

Publication number
HK1191330A1
HK1191330A1 HK14104405.5A HK14104405A HK1191330A1 HK 1191330 A1 HK1191330 A1 HK 1191330A1 HK 14104405 A HK14104405 A HK 14104405A HK 1191330 A1 HK1191330 A1 HK 1191330A1
Authority
HK
Hong Kong
Prior art keywords
mglur5
positive allosteric
allosteric modulators
ethynyl derivatives
ethynyl
Prior art date
Application number
HK14104405.5A
Other languages
English (en)
Inventor
喬治．耶施克
西内塞．若利多
洛塔爾．林德曼
海因茨．施塔德勒
埃里克．維埃拉
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1191330A1 publication Critical patent/HK1191330A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
    • Y02P70/50—Manufacturing or production processes characterised by the final manufactured product
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/60—Other road transportation technologies with climate change mitigation effect
    • Y02T10/70—Energy storage systems for electromobility, e.g. batteries
HK14104405.5A 2011-04-26 2014-05-09 作為 的正變構調節劑的乙炔基衍生物 HK1191330A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163683 2011-04-26
PCT/EP2012/057335 WO2012146551A1 (en) 2011-04-26 2012-04-23 Ethynyl derivatives as positive allosteric modulators of the mglur5

Publications (1)

Publication Number Publication Date
HK1191330A1 true HK1191330A1 (zh) 2014-07-25

Family

ID=46025665

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14104405.5A HK1191330A1 (zh) 2011-04-26 2014-05-09 作為 的正變構調節劑的乙炔基衍生物

Country Status (33)

Country Link
US (2) US8957213B2 (zh)
EP (1) EP2702051B1 (zh)
JP (1) JP5753627B2 (zh)
KR (1) KR101554803B1 (zh)
CN (1) CN103492373B (zh)
AR (1) AR086036A1 (zh)
AU (1) AU2012247653B2 (zh)
BR (1) BR112013026116A2 (zh)
CA (1) CA2829170C (zh)
CL (1) CL2013003056A1 (zh)
CO (1) CO6801734A2 (zh)
CR (1) CR20130475A (zh)
CY (1) CY1116391T1 (zh)
DK (1) DK2702051T3 (zh)
EA (1) EA022019B1 (zh)
ES (1) ES2534090T3 (zh)
HK (1) HK1191330A1 (zh)
HR (1) HRP20150555T1 (zh)
HU (1) HUE025031T2 (zh)
IL (1) IL228835A (zh)
MA (1) MA35133B1 (zh)
MX (1) MX337443B (zh)
MY (1) MY163164A (zh)
PE (1) PE20141169A1 (zh)
PL (1) PL2702051T3 (zh)
PT (1) PT2702051E (zh)
RS (1) RS53903B1 (zh)
SG (1) SG194120A1 (zh)
SI (1) SI2702051T1 (zh)
TW (2) TW201306355A (zh)
UA (1) UA110378C2 (zh)
WO (1) WO2012146551A1 (zh)
ZA (1) ZA201306586B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012247653B2 (en) * 2011-04-26 2016-05-26 F. Hoffmann-La Roche Ag Ethynyl derivatives as positive allosteric modulators of the mGluR5
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
EP2875000B1 (en) * 2012-07-17 2016-09-21 F. Hoffmann-La Roche AG Arylethynyl derivatives
ES2599507T3 (es) * 2012-10-18 2017-02-02 F. Hoffmann-La Roche Ag Derivados de etinilo como moduladores de la actividad del receptor mGluR5
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
HUE048867T2 (hu) * 2015-06-03 2020-08-28 Hoffmann La Roche Etinil-származékok
KR20180026438A (ko) 2015-07-15 2018-03-12 에프. 호프만-라 로슈 아게 대사형 글루타메이트 수용체 조절제로서의 에틴일 유도체
US10423423B2 (en) 2015-09-29 2019-09-24 International Business Machines Corporation Efficiently managing speculative finish tracking and error handling for load instructions
ES2826389T3 (es) 2016-07-18 2021-05-18 Hoffmann La Roche Derivados de etinilo
CA3077088A1 (en) * 2017-10-10 2019-04-18 Biogen Inc. Process for preparing spiro derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP5635727B2 (ja) * 2004-10-07 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP2029559B1 (en) 2006-05-31 2009-08-05 F. Hoffmann-Roche AG Aryl-4-ethynyl-isoxazole derivatives
MX2009013169A (es) * 2007-06-03 2010-04-30 Univ Vanderbilt Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos.
US8034806B2 (en) * 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
AU2012247653B2 (en) * 2011-04-26 2016-05-26 F. Hoffmann-La Roche Ag Ethynyl derivatives as positive allosteric modulators of the mGluR5

Also Published As

Publication number Publication date
EA201391537A1 (ru) 2014-04-30
PL2702051T3 (pl) 2015-08-31
IL228835A0 (en) 2013-12-31
JP5753627B2 (ja) 2015-07-22
TW201311657A (zh) 2013-03-16
RS53903B1 (en) 2015-08-31
TW201306355A (zh) 2013-02-01
CA2829170C (en) 2019-02-26
CN103492373B (zh) 2015-09-16
CY1116391T1 (el) 2017-02-08
CN103492373A (zh) 2014-01-01
US20120277213A1 (en) 2012-11-01
HUE025031T2 (en) 2016-02-29
EP2702051A1 (en) 2014-03-05
US9212171B2 (en) 2015-12-15
AU2012247653B2 (en) 2016-05-26
IL228835A (en) 2016-02-29
KR101554803B1 (ko) 2015-09-21
ES2534090T3 (es) 2015-04-17
NZ614688A (en) 2015-09-25
WO2012146551A1 (en) 2012-11-01
MX2013011105A (es) 2013-10-17
BR112013026116A2 (pt) 2016-12-27
MY163164A (en) 2017-08-15
MA35133B1 (fr) 2014-05-02
CO6801734A2 (es) 2013-11-29
HRP20150555T1 (hr) 2015-07-03
CA2829170A1 (en) 2012-11-01
AU2012247653A1 (en) 2013-09-26
SG194120A1 (en) 2013-11-29
US8957213B2 (en) 2015-02-17
UA110378C2 (en) 2015-12-25
US20150119384A1 (en) 2015-04-30
JP2014512401A (ja) 2014-05-22
AR086036A1 (es) 2013-11-13
EP2702051B1 (en) 2015-03-04
EA022019B1 (ru) 2015-10-30
SI2702051T1 (sl) 2015-06-30
MX337443B (es) 2016-03-07
DK2702051T3 (en) 2015-03-16
CL2013003056A1 (es) 2014-07-25
ZA201306586B (en) 2014-05-28
CR20130475A (es) 2013-11-11
PT2702051E (pt) 2015-05-20
PE20141169A1 (es) 2014-09-22
TWI436993B (zh) 2014-05-11
KR20140014256A (ko) 2014-02-05

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HK1210180A1 (zh) 白樺脂醇的衍生物
EP2680849A4 (en) 6-ALKYL-N- (PYRIDIN-2-YL) -4-ARYLOXYPICOLINAMIDE ANALOGUES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 AND PROCESS FOR PREPARING AND USING SAME
ZA201306175B (en) Isoxazole derivatives
IL227664A0 (en) New heterocyclic histories
HK1191330A1 (zh) 作為 的正變構調節劑的乙炔基衍生物
ZA201206095B (en) Process for the preparation of isoxazoline derivatives
HK1195298A1 (zh) 作為 變構調節劑的乙炔基衍生物
IL247635A0 (en) History of isoxazole
EP2709609A4 (en) HETEROCYCLIC COMPOUNDS
ZA201307428B (en) Thiazole derivatives
HK1179956A1 (zh) 作為 調節劑的稠合雜環衍生物
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
PL2769720T3 (pl) Heterocykliczne allosteryczne modulatory gsk-3
AU2016202292A1 (en) Derivatives of betulin